Company Filing History:
Years Active: 2012-2015
Title: Inko Nimmrich: Innovator in Breast Cancer Prognosis
Introduction
Inko Nimmrich is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of cancer research, particularly in breast cancer prognosis. With a total of 2 patents, his work focuses on innovative methods for predicting disease outcomes in patients.
Latest Patents
Nimmrich's latest patents include groundbreaking inventions aimed at improving breast cancer prognosis. The first patent, titled "Methods for the prognosis of breast cancer," relates to modified and genomic sequences, as well as oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA. This invention also provides a method for predicting disease-free survival and response to endocrine treatment in subjects with cell proliferative disorders of breast tissues. The second patent, "Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy," similarly focuses on genomic sequences and oligonucleotides for assessing the risk of relapse in patients undergoing treatment.
Career Highlights
Inko Nimmrich is associated with Epigenomics AG, a company dedicated to developing innovative cancer diagnostics. His work at Epigenomics AG has positioned him as a key player in the advancement of personalized medicine for breast cancer patients.
Collaborations
Throughout his career, Nimmrich has collaborated with esteemed colleagues such as John Foekens and Nadia Harbeck. These partnerships have further enhanced the impact of his research and innovations in the field.
Conclusion
Inko Nimmrich's contributions to breast cancer prognosis through his patents and work at Epigenomics AG highlight his commitment to improving patient outcomes. His innovative methods are paving the way for advancements in cancer treatment and diagnostics.